A rising tide lifts all boats. Amarin is trying to capitalize off this investor / pharma interest and hoping to pick up scripts in this high trig segment if insurers want a cheaper option that serves the patient population of Ionis and Arrowhead
Sagaponack, ponder this idea, V has the possibility of becoming a tier 2 drug, one step away from the generics. No need to go for the branded generic idea. 🤔
Those 2 companies are not trading at their current valuation because of their triglyceride drugs. Both have huge pipelines with around 25 active trials in a variety of indications ions is 12b and arwr 8b. They cannot be compared to amrn because of 1 drug treating same indication https://ionis.com/science-and-innovation/pipeline